Skip to main content
Fig. 3 | Trials

Fig. 3

From: Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis

Fig. 3

Flowchart. Green boxes indicate assessment of remission. Brown boxes indicate medication dosage-related events (maintaining, intensifying, and tapering treatment). Red boxes indicate patient dropouts. Blue diamonds indicate decisions for patient-tailored treatment. Orange boxes refer to current medication dosages. Clinical remission is remission according to ACR/EULAR 2011 Boolean remission criteria [10]. HandScan remission remission is achieved if total optical spectral transmission (OST) score ≤ 11 AND a maximum of one joint with OST > 1. MTX methotrexate, LEF leflunomide, PRED prednisolone, HCQ hydroxychloroquine, aTNF tumour necrosis factor inhibitor, MTX at max maximum (tolerable) dose, i.e., 30 mg or lower, or maximal tolerable dose, AE adverse event or effect, ML medication level

Back to article page

Trials

ISSN: 1745-6215